Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Nat Genet. 2009 Sep 27;41(10):1133–1137. doi: 10.1038/ng.451

Figure 3. Rac2 suppression impairs lymphoma cell migration and extends animal survival.

Figure 3

(A) Rac2 suppression causes defects in short term engraftment. Lymphoma cells expressing dsCherry or coexpressing GFP and shRac2 were mixed, injected into recipient mice, and assessed after 2 or 24 hours. p-values were determined by one-way ANOVA or a one-sample t-test. Bar graphs represent mean and standard deviation. n=1 for injected cells, n=3 for all other experimental groups. (B) Lymphoma cells suppressing Wave2 were depleted in an in vivo GFP competition assay. p-values were determined by a two-tailed Student's t-test. (n=7 for vector control, n=4 for shWave2-1). (C) Suppression of Rac2 impairs lymphoma cell migration to the lymph nodes and liver. 14 days after transplantation, shRac2 recipients show markedly reduced tumor dissemination. (D) Partially-transduced lymphoma cells were harvested from the liver at the time of disease presentation and the percentage of GFP positive cells was assessed. p-values were determined by one-way ANOVA. (n=7 for vector control, n=4 for shRac2-1 and shRac2-2) (E and F) Suppression of Rac2 in lymphoma cells delays disease progression. GFP sorted lymphoma cells were injected into recipient mice. Survival is displayed in Kaplan-Meier format (n=5 mice per group for tumor free survival and n=10 mice per group for overall survival).